naltrexone has been researched along with Cardiovascular Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gorelik, B; Gorelik, E; Hirsh-Raccah, B; Masarwa, R; Matok, I; Perlman, A | 1 |
| Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H | 1 |
| Jatlow, PI; Mayne, ST; O'Malley, SS; Wu, R | 1 |
| Cunningham, JW; Wiviott, SD | 1 |
| Psaty, BM; Sharfstein, JM | 1 |
| Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE | 1 |
| Lewis, RJ; Tolles, J | 1 |
| Wise, J | 1 |
| Astrup, A | 1 |
1 review(s) available for naltrexone and Cardiovascular Diseases
| Article | Year |
|---|---|
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Fructose; Heart; Humans; Naltrexone; Obesity; Phentermine; Topiramate | 2014 |
3 trial(s) available for naltrexone and Cardiovascular Diseases
| Article | Year |
|---|---|
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Feeding Behavior; Female; Humans; Hypertension; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Overweight; Quality of Life; Risk Factors; Weight Loss | 2013 |
Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease.
Topics: Administration, Cutaneous; Adult; Antioxidants; Bilirubin; Cardiovascular Diseases; Counseling; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Naltrexone; Nicotine; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Treatment Outcome | 2014 |
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Topics: Aged; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Bupropion; Cardiovascular Diseases; Confidence Intervals; Confidentiality; Double-Blind Method; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Humans; Internet; Male; Middle Aged; Myocardial Infarction; Naltrexone; Obesity; Overweight; Patient Selection; Placebo Effect; Risk Factors; Sample Size; United States; Weight Reduction Programs | 2016 |
6 other study(ies) available for naltrexone and Cardiovascular Diseases
| Article | Year |
|---|---|
The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-Obesity Agents; Benzazepines; Cardiovascular Diseases; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Phentermine; United States; United States Food and Drug Administration | 2020 |
Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted.
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Female; Humans; Male; Naltrexone; Obesity | 2016 |
Time-to-Event Analysis.
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Female; Humans; Male; Naltrexone; Obesity | 2016 |
Company is blamed for early halt of trial into obesity treatment.
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Early Termination of Clinical Trials; Female; Humans; Male; Naltrexone; Obesity | 2016 |
Is cardiometabolic risk improved by weight-loss drugs?
Topics: Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Risk Factors | 2010 |
New obesity pill: new hopes, old fears.
Topics: Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Approval; Drug Combinations; Exercise; Feeding Behavior; Humans; Life Style; Naltrexone; Narcotic Antagonists; Obesity; Seizures; Suicidal Ideation; United States; United States Food and Drug Administration | 2010 |